– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator – – Significantly greater...
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on...
RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will...
Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News...
LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company...
CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), is announcing today that its Vice President and Chief Financial Officer, Jay Saccaro, will be...
Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite...
Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024...
LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising...
KNOXVILLE, TN, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that...
BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
Dr. Yelena Janjigian, Chief of GI Cancers, Leads Investigator Sponsored Study at Memorial Sloan Kettering Cancer CenterTrial is Supported by...
Up to 16 million adults in the US are living with a neurological disease, the leading cause of physical and...
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in FullSOLANA BEACH, Calif., Feb. 14, 2024...
With the Response Rate increasing to 23%, MDNA11 continues to show compelling single-agent activity in the ABILITY-1 study amongst high-dose...
Company positioned at forefront of $208 billion global AI in healthcare market by 2030 PLEASANTON, Calif., Feb. 14, 2024 (GLOBE...
TScan’s abstract selected by the Tandem Meetings to receive a Best Abstracts Award Company to discuss the potential implications of...
More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical...
COAST trial is evaluating the superiority of sozinibercept combined with EYLEA® (aflibercept) over EYLEA alone in wet AMD Enrollment of...
Chimeric Bait Receptors for Combatting Airborne Viral Infections Can Be Delivered IntranasallyLONDON, UK / ACCESSWIRE / February 14, 2024 /...